[1]孙璇,王阶,刘兰椿.从“气”探析心系疾病与线粒体功能障碍关系[J].陕西中医,2026,(8):1068-1073.[doi:DOI:10.3969/j.issn.1000-7369.2026.08.010]
　SUN Xuan,WANG Jie,LIU Lanchun.Exploring relationship between cardiovascular diseases and mitochondrial dysfunction from perspective of Qi[J].,2026,(8):1068-1073.[doi:DOI:10.3969/j.issn.1000-7369.2026.08.010]
点击复制

从“气”探析心系疾病与线粒体功能障碍关系

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年8期
页码:
1068-1073
栏目:
学术探讨
出版日期:
2026-08-05

文章信息/Info

Title:
Exploring relationship between cardiovascular diseases and mitochondrial dysfunction from perspective of Qi
作者:
孙璇; 王阶; 刘兰椿
（中国中医科学院广安门医院，北京 100032）
Author(s):
SUN Xuan; WANG Jie; LIU Lanchun
(Guang’anmen Hospital,China Academy of Chinese Medical Sciences,Beijing 100032,China)
关键词:
心系疾病; 线粒体; 气; 能量代谢; 氧化应激; 线粒体质量控制; 从气论治
Keywords:
Cardiovascular diseases; Mitochondria; Qi; Energy metabolism; Oxidative stress; Mitochondrial quality control; Qi-based treatment
分类号:
R 816.2
DOI:
DOI:10.3969/j.issn.1000-7369.2026.08.010
文献标志码:
A
摘要:
心系疾病的发生发展与心肌能量代谢、氧化还原稳态、钙信号调控及细胞死亡过程密切相关。线粒体作为物质代谢和能量转换的核心细胞器，其功能障碍贯穿动脉粥样硬化、冠心病、心律失常、心力衰竭等病变过程。线粒体DNA异常、氧化磷酸化受损、活性氧过量生成、钙稳态失衡、线粒体自噬及分裂融合失调，可造成心肌细胞结构和功能损伤，并与疾病进展形成相互促进的病理循环。气为生命活动之本，具有推动、温煦、防御、固摄和气化等功能，其生成依赖先天之精、水谷精微与自然清气，运行则体现为升降出入及脏腑经络的协同作用。基于中西医理论互参，线粒体与“气”在源、用、机、治层面具有一定相通性。线粒体作为细胞稳态调控的重要枢纽，从微观层面阐释气的化生、运行及充养心脉之功；其功能失衡所致心肌供能不足、内环境紊乱和损伤累积，可与心气不足、气机失调、气虚血瘀及脏腑气化失司等病机相互印证。从气论治心系疾病应结合疾病类型、证候特点及线粒体损伤环节，分别从调补宗气、平衡阴阳二气、调和营卫、整体调节脏腑之气等方面确立治法，改善线粒体生物合成、能量代谢、氧化应激、膜电位稳定性及质量控制。该理论框架有助于阐释中医辨证论治心系疾病的微观基础，为中西医协同干预及后续机制研究提供思路。
Abstract:
Occurrence and progression of cardiovascular diseases were closely associated with myocardial energy metabolism,redox homeostasis,calcium signaling regulation,and cell death.As core organelle involved in metabolism and energy conversion,mitochondrial dysfunction was involved throughout pathological processes of atherosclerosis,coronary heart disease,arrhythmia,and heart failure.Mitochondrial DNA abnormalities,impaired oxidative phosphorylation,excessive reactive oxygen species production,calcium homeostasis imbalance,and dysregulation of mitophagy and mitochondrial fission-fusion dynamics could jointly lead to structural and functional injury of cardiomyocytes and form a mutually reinforcing pathological cycle with disease progression.Qi was regarded as the basis of life activities and had functions of promotion,warming,defense,consolidation,and transformation.Its generation depends on innate essence,essence of water and grain,and natural clear Qi,while its movement was manifested as ascending,descending,entering,and exiting,as well as the coordinated action of the Zangfu organs and meridians.Based on integrative understanding of Chinese and Western medicine,mitochondria and Qi share certain similarities in origin,function,pathogenesis,and treatment.As an important hub of cellular homeostasis regulation,mitochondria may provide a microscopic explanation for the generation and movement of Qi and its role in nourishing the heart vessels.Mitochondrial dysfunction-induced myocardial energy deficiency,homeostatic disturbance,and cumulative injury can correspond to such pathological changes as heart Qi deficiency,Qi movement disorder,Qi deficiency and blood stasis,and dysfunction of Zangfu Qi transformation.Accordingly,Qi-based treatment of cardiovascular diseases should be established according to disease type,syndrome characteristics,and specific links of mitochondrial injury.Therapeutic strategies may include supplementing and regulating Zong Qi,balancing Yin and Yang Qi,harmonizing nutrient and defensive Qi,and integrally regulating Zangfu Qi.To improve mitochondrial biogenesis,energy metabolism,oxidative stress,mitochondrial membrane potential stability,and quality control.This theoretical framework may help elucidate the microscopic basis of syndrome differentiation and treatment of cardiovascular diseases in traditional Chinese medicine and provide ideas for integrated Chinese and western medical intervention and subsequent mechanistic studies.

参考文献/References:

[1]ZHANG R,JIANG Y,ZHANG G,et al.Mitochondrial DNA in atherosclerosis：Mechanisms biomarker potential and therapeutic perspectives[J].Int Immunopharmacol,2025,152：114449.
[2]林飞,王阶,郭欣桐,等.基于线粒体DNA探析体质学说对冠心病发病机制的影响[J].中华中医药杂志,2015,30(9)：3250-3252.
[3]BACCARELLI A A,BYUN H M.Platelet mitochondrial DNA methylation：A potential new marker of cardiovascular disease[J].Clin Epigenetics,2015,7(1)：44.
[4]LIU Y F,ZHU J J,TIAN X Y,et al.Hypermethylation of mitochondrial DNA in vascular smooth muscle cells impairs cell contractility[J].Cell Death Dis,2020,11(1)：35.
[5]FU X,ZHAO Y,KE Y,et al.Mitochondrial DNA copy number and risk of cardiovascular disease and all-cause mortality：A systematic review and meta-analysis of observational studies[J].QJM,2025,118(1)：5-15.
[6]YANG H M.Mitochondrial dysfunction in cardiovascular diseases[J].Int J Mol Sci,2025,26(5)：1917.
[7]LOPASCHUK G D,KARWI Q G,TIAN R,et al.Cardiac energy metabolism in heart failure[J].Circ Res,2021,128(10)：1487-1513.
[8]HINTON A J,CLAYPOOL S M,NEIKIRK K,et al.Mitochondrial structure and function in human heart failure[J].Circ Res,2024,135(2)：372-396.
[9]姜文睿,王阶.透过慢性心力衰竭探讨宗气与心肌线粒体的关系[J].中华中医药杂志,2017,32(5)：2084-2086.
[10]杨世伟,杨添淞,冯楚文,等.磷酸酶及张力蛋白同源物诱导激酶/帕金森病蛋白介导的线粒体自噬对患者心肌损伤产生影响的研究进展[J].陕西医学杂志,2024,53(4)：569-572.
[11]郑标,王琼,肖玉波,等.线粒体自噬在动脉粥样硬化中作用的研究进展[J].中国病理生理杂志,2025,41(3)：585-592.
[12]佘丽萍,王垚,黄敏,等.线粒体自噬受体FUNDC1在脓毒症大鼠心肌损伤中对氧化应激响应的调控[J].陕西医学杂志,2025,54(4)：441-446.
[13]ZANFARDINO P,AMATI A,PERRONE M,et al.The balance of MFN2 and OPA1 in mitochondrial dynamics cellular homeostasis and disease[J].Biomolecules,2025,15(3)：433.
[14]WANG N,WANG X,LAN B,et al.DRP1 fission and apoptosis[J].Cell Death Discov,2025,11(1)：150.
[15]FORTE M,SCHIRONE L,AMERI P,et al.The role of mitochondrial dynamics in cardiovascular diseases[J].Br J Pharmacol,2021,178(10)：2060-2076.
[16]WAI T,GARCIA-PRIETO J,BAKER M J,et al.Imbalanced OPA1 processing and mitochondrial fragmentation cause heart failure in mice[J].Science,2015,350(6265)：116.
[17]BLAND A R,PAYNE F M,ASHTON J C,et al.The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury[J].Pharmacol Res,2022,175：105986.
[18]HEUSCH G,ANDREADOU I,BELL R,et al.Health position paper and redox perspectives on reactive oxygen species as signals and targets of cardioprotection[J].Redox Biol,2023,68：102894.
[19]WU C,ZHANG Z,ZHANG W,et al.Mitochondrial dysfunction and mitochondrial therapies in heart failure[J].Pharmacol Res,2022,175：106038.
[20]AJOOLABADY A,CHIONG M,LAVANDERO S,et al.Mitophagy in cardiovascular diseases：Molecular mechanisms pathogenesis and treatment[J].Trends Mol Med,2022,28(10)：836-849.
[21]SCHEFFER D D L,GARCIA A A,LEE L,et al.Mitochondrial fusion fission and mitophagy in cardiac diseases：Challenges and therapeutic opportunities[J].Antioxid Redox Signal,2022,36(10)：844-863.
[22]DA DALT L,CABODEVILLA A G,GOLDBERG I J,et al.Cardiac lipid metabolism mitochondrial function and heart failure[J].Cardiovasc Res,2023,119(9)：1905-1918.
[23]QIN P,QIN T,LIANG L,et al.The role of mitochondrial DNA copy number in cardiometabolic disease：A bidirectional two-sample mendelian randomization study[J].Cardiovasc Diabetol,2024,23：37.
[24]GUO Y,YOU Y,SHANG F F,et al.iNOS aggravates pressure overload-induced cardiac dysfunction via activation of the cytosolic-mtDNA-mediated cGAS-STING pathway[J].Theranostics,2023,13(12)：4051-4067.
[25]LEI Y,VANPORTFLIET J J,CHEN Y F,et al.Cooperative sensing of mitochondrial DNA by ZBP1 and cGAS promotes cardiotoxicity[J].Cell,2023,186(14)：3013-3032.
[26]SUBIRA J,SORIANO M J,DELCASTILLO L M,et al.Mitochondrial replacement techniques to resolve mitochondrial dysfunction and ooplasmic deficiencies：Where are we now?[J].Hum Reprod,2025,40(4)：585-600.
[27]沈娱汀,李娟,宋云,等.内质网-线粒体接触与抗病毒免疫应答[J].中国免疫学杂志,2021,37(11)：1386-1390.
[28]王效琰,苑海涛,梁馨月.线粒体膜通透性转换孔与心肌缺血再灌注损伤的研究进展[J].中华老年心脑血管病杂志,2025,27(3)：377-379.
[29]宋飞飞,范英丽,刘彬,等.四君子汤对脾气虚证模型大鼠股四头肌线粒体分裂蛋白表达的影响[J].时珍国医国药,2022,33(3)：546-548.
[30]高若原,高靖然,赵浩宇,等.基于“线粒体动力学”探讨中药补气机制[J].中国中药杂志,2023,48(13)：3684-3692.
[31]周维祥,吴旸,李星星,等.黄芪多糖干预气虚型心力衰竭大鼠心肌细胞线粒体能量代谢的作用机制[J].世界中医药,2025,20(24)：4423-4431.
[32]ZHANG S,TANG F,YANG Y,et al.Astragaloside Ⅳ protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis[J].PLoS One,2015,10(3)：118759.
[33]LUO J,SHEN S,XIA J,et al.Mitochondria as the essence of Yang Qi in the human body[J].Phenomics,2022,2(5)：336-348.
[34]倪雅娟,白鸿远,朱文静,等.松果菊苷通过上调PGC-1/NFR信号通路促进线粒体生物合成抑制心肌细胞凋亡[J].西安交通大学学报(医学版),2022,43(4)：607-611.
[35]WANG Z,SU G,ZHANG Z,et al.25-Hydroxyl-protopanaxatriol protects against H2O2-induced H9c2 cardiomyocytes injury via PI3K/Akt pathway and apoptotic protein down-regulation[J].Biomed Pharmacother,2018,99：33-42.
[36]侯承志,陈兴娟,胡哲恺,等.基于“损其心者,调其营卫”探讨快速型心律失常的辨治[J].中国中医基础医学杂志,2022,28(4)：663-666.
[37]陈佳永,庞延,潘朝锌,等.基于心肌能量代谢探讨中医药防治心力衰竭研究进展[J].陕西中医,2024,45(7)：1002-1005.
[38]蒋沈华,虞坚尔,冯其茂.中药保护线粒体功能在慢性心力衰竭治疗中的应用进展[J].陕西中医,2024,45(7)：1006-1009.
[39]孙璇,王阶,张振鹏,等.补肾法治疗泛血管“免疫-代谢-遗传”轴机制[J].中国实验方剂学杂志,2026,32(1)：1-11.
[40]谢抗,李春,王勇,等.基于心力衰竭“脾-线粒体-心”轴探讨“心受气于脾”的理论内涵[J].中华中医药学刊,2024,42(10)：118-122.
[41]崔志洁,高铸烨,姜众会,等.基于“脾主肌肉”理论探讨线粒体质量控制在心力衰竭合并肌少症中医药治疗中的价值[J].陕西中医,2025,46(6)：795-799.
[42]李玉洁,韩萌,杨国宁,等.芪参益气滴丸对慢性心衰大鼠线粒体分裂-融合及丝裂原活化蛋白激酶/细胞外信号调节激酶信号通路的影响[J].陕西医学杂志,2025,54(4)：465-469,486.

相似文献/References:

[1]屈红艳,邢文文,李 璐,等.针灸调节阿尔茨海默病患者线粒体SIRT3机制初探*[J].陕西中医,2019,(2):244.
　QU Hongyan,XING Wenwen,LI Lu,et al.Relevant research on Alzheimer’s disease and regulating silent information regulator 3 by acupunture[J].,2019,(8):244.
[2]张洁洁,孟 伟.名中医郭维琴基于“脏-神-气”论治心系疾病郁证经验[J].陕西中医,2023,(7):933.[doi:DOI:10.3969/j.issn.1000-7369.2023.07.025]
[3]张璐,韩俊泉,王红.名中医王红治疗代谢相关脂肪性肝病临床经验[J].陕西中医,2025,46(6):813.[doi:DOI:10.3969/j.issn.1000-7369.2025.06.019]
　ZHANG Lu,HAN Junquan,WANG Hong.WANG Hong’s clinical experience in treating metabolic associated fatty liver disease[J].,2025,46(8):813.[doi:DOI:10.3969/j.issn.1000-7369.2025.06.019]
[4]赵恩熙,李乐愚,李娜,等.基于“脾虚-浊瘀-热毒”理论探讨2型糖尿病铁死亡的科学内涵[J].陕西中医,2025,46(8):1077.[doi:DOI:10.3969/j.issn.1000-7369.2025.08.013]
　ZHAO Enxi,LI Leyu,LI Na,et al.To explore the scientific connotation of ferroptosis in T2DM based on the theory of “spleen deficiency-phlegm and stasis-heat toxin”[J].,2025,46(8):1077.[doi:DOI:10.3969/j.issn.1000-7369.2025.08.013]

备注/Memo

备注/Memo:
国家自然科学基金重点资助项目（82230124）；中央高水平中医医院临床科研业务项目（HLCMHPP2023083）；国家中医药管理局第二届全国名中医传承工作室建设项目（国中医药办人教函〔2022〕245号）；国家中医药管理局全国名老中医药专家传承工作室建设项目（国中医药人教函〔2022〕75号）
更新日期/Last Update: 2026-08-13